Robert James
Chair of Board and Director


Robert has worked in the commercial exploitation of intellectual property for more than 20 years. He first worked at Cancer Research Campaign Technology (now Cancer Research UK Commercial Partnerships) for seven years before moving to the early stage venture capital company, Prelude Ventures. He was a founding Partner of DFJ Esprit before leaving in 2010 to create Sixth Element Capital LLP which raised the $100m CRT Pioneer Fund.

Robert has been involved in many early stage technologies and businesses which, in aggregate, have raised over several hundred million pounds financing and has been involved in raising four VC funds. He played a central role in licensing Temodal (a billion dollar drug) to Schering Plough and the recently approved PARP inhibitor, Rubraca, to Agouron (now Clovis); he has been lead investor in successful life science technologies and businesses in diagnosis, tools and therapeutics such as Oxford Immunotec (Nasdaq:OXFD), Kiadis (Euronext:KDS) and DNA Research Innovations (now owned by ThermoFisher Scientific). Whilst at Sixth Element he has been a key part of the management team that has built a 13 investment portfolio and in the licensing of two projects to Sierra Oncology and Boston Pharmaceuticals. Robert has a PhD in Biochemistry and a degree in Genetics.